Raloxifene hydrochloride

• Product NameRaloxifene hydrochloride
  CAS No.82640-04-8
  Purity99%
  Min Quantity5000Kilograms
  Price1~100
• View Contact Detail

• 
  Molecular Structure

Detailed Description


Alias: Raloxifene hydrochloride,Raloxifene HCl
CAS Registry Number: 82640-04-8
Assay: 99%
Molecular Formula: C28H28ClNO4S
Molecular weight: 510.05
Appearance: white crystalline powder
Grade:Pharmaceutical Grade


Raloxifene (marketed as Evista) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Raloxifene helps to preserve bone mass, but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.

Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.

Raloxifene is used to prevent and treat bone loss (osteoporosis) in women after menopause. Maintaining strong bones by slowing bone loss helps to reduce the risk of fractures.

Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.